The estimated Net Worth of Inc Pfizer Ventures (Us) Ll... is at least $6.34 Million dollars as of 13 May 2019. Inc Ll owns over 50,000 units of Cortexyme Inc stock worth over $6,337,447 and over the last 6 years Inc sold CRTX stock worth over $0.
Inc has made over 1 trades of the Cortexyme Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Inc bought 50,000 units of CRTX stock worth $850,000 on 13 May 2019.
The largest trade Inc's ever made was buying 50,000 units of Cortexyme Inc stock on 13 May 2019 worth over $850,000. On average, Inc trades about 50,000 units every 0 days since 2019. As of 13 May 2019 Inc still owns at least 3,249,973 units of Cortexyme Inc stock.
You can see the complete history of Inc Ll stock trades at the bottom of the page.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi und Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: